Vanguard Investments Australia
APGE icon

Vanguard Investments Australia’s Apogee Therapeutics APGE Stock Holding History

Vanguard Investments Australia’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Hold
9,647
– – ﹤0.01% 1128
2026
Q1 		$812K Buy
+9,647
New +$701K ﹤0.01% 1316

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Vanguard Investments Australia's APGE Position: Q2 2026 in Review

Vanguard Investments Australia held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 9,647 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1128.

Vanguard Investments Australia first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vanguard Investments Australia held 9,647 shares of Apogee Therapeutics worth $1.28M as of Q2 2026.
  • Vanguard Investments Australia left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1128 holding.
  • Vanguard Investments Australia first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.